IN8bio Receives FDA Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed Glioblastoma

IN8bio, Inc. announced FDA orphan drug designation for INB-400 and INB-410, covering a broad range of malignant glioma treatments, including newly diagnosedglioblastoma multiforme, marking the first-ever orphan drug designation for genetically modified gamma-delta T cell therapies.